CN109414510B - Mt1-mmp特异性双环肽-毒素缀合物 - Google Patents

Mt1-mmp特异性双环肽-毒素缀合物 Download PDF

Info

Publication number
CN109414510B
CN109414510B CN201780031804.XA CN201780031804A CN109414510B CN 109414510 B CN109414510 B CN 109414510B CN 201780031804 A CN201780031804 A CN 201780031804A CN 109414510 B CN109414510 B CN 109414510B
Authority
CN
China
Prior art keywords
peptide
acid
bicyclic
amino acid
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780031804.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109414510A (zh
Inventor
D·托伊费尔
S·帕万
L·巴尔达萨雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bicycle Therapeutics PLC
Original Assignee
Bicycle Therapeutics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycle Therapeutics PLC filed Critical Bicycle Therapeutics PLC
Publication of CN109414510A publication Critical patent/CN109414510A/zh
Application granted granted Critical
Publication of CN109414510B publication Critical patent/CN109414510B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780031804.XA 2016-05-04 2017-05-04 Mt1-mmp特异性双环肽-毒素缀合物 Active CN109414510B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1607827.1A GB201607827D0 (en) 2016-05-04 2016-05-04 Bicyclic peptide-toxin conjugates specific for MT1-MMP
GB1607827.1 2016-05-04
PCT/GB2017/051250 WO2017191460A1 (en) 2016-05-04 2017-05-04 Bicyclic peptide-toxin conjugates specific for mt1-mmp

Publications (2)

Publication Number Publication Date
CN109414510A CN109414510A (zh) 2019-03-01
CN109414510B true CN109414510B (zh) 2022-07-19

Family

ID=56234400

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780031804.XA Active CN109414510B (zh) 2016-05-04 2017-05-04 Mt1-mmp特异性双环肽-毒素缀合物

Country Status (8)

Country Link
US (1) US10994019B2 (https=)
EP (1) EP3452096B1 (https=)
JP (1) JP6942147B2 (https=)
CN (1) CN109414510B (https=)
DK (1) DK3452096T3 (https=)
ES (1) ES3010545T3 (https=)
GB (1) GB201607827D0 (https=)
WO (1) WO2017191460A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
EP3544621A1 (en) 2016-11-27 2019-10-02 BicycleRD Limited Methods for treating cancer
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
KR20190125310A (ko) 2017-03-10 2019-11-06 퀴아펙 파마슈티칼스 에이비 방출가능한 접합체
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
WO2019034868A1 (en) * 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) * 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
KR20220127380A (ko) 2018-03-09 2022-09-19 퀴아펙 파마슈티칼스 에이비 방출가능한 항체 접합체
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
CA3112473A1 (en) 2018-09-12 2020-03-19 Quiapeg Pharmaceuticals Ab Releasable glp-1 conjugates
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2020120984A1 (en) * 2018-12-13 2020-06-18 Bicycletx Limited Bicyclic peptide ligands specific for mt1-mmp
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020128527A1 (en) * 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
GB201900526D0 (en) * 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
WO2020225577A1 (en) * 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI869398B (zh) 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
CN112048013B (zh) * 2019-06-05 2021-11-05 深圳先进技术研究院 靶向脑胶质瘤的多肽化合物及其合成方法与应用
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
SMT202500247T1 (it) 2019-10-03 2025-09-12 Bicycletx Ltd Complessi peptidici eterotandem biciclici
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
CN118103388A (zh) * 2021-10-14 2024-05-28 西藏海思科制药有限公司 EphA2的双环肽配体及其缀合物
WO2023088236A1 (zh) * 2021-11-16 2023-05-25 海思科医药集团股份有限公司 Mt1-mmp的双环肽配体及其缀合物
GB202214528D0 (en) 2022-10-03 2022-11-16 Owlstone Med Ltd A compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600911D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60336149D1 (de) * 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
EP1618897A4 (en) * 2003-04-04 2010-09-29 Eisai R&D Man Co Ltd LIPID MEMBRANE STRUCTURE COMPRISING AN ANTI-MT-MMP MONOCLONAL ANTIBODY
WO2006078161A1 (en) 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
EP2653545A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
JP2013518558A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 構造化されたペプチドプロセシング
PL2764140T3 (pl) * 2011-10-07 2018-04-30 Bicyclerd Limited Modulacja specyficzności polipeptydów ustrukturyzowanych
US20140274759A1 (en) 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
ES2715379T3 (es) 2013-10-28 2019-06-04 Bicyclerd Ltd Novedosos polipéptidos
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
EP3544621A1 (en) 2016-11-27 2019-10-02 BicycleRD Limited Methods for treating cancer
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
US20190389907A1 (en) 2016-12-23 2019-12-26 Bicycletx Limited Peptide ligands for binding to mt1-mmp
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
EP3774851A1 (en) 2018-04-04 2021-02-17 BicycleTX Limited Heterotandem bicyclic peptide complexes
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
SG11202104356VA (en) 2018-10-30 2021-05-28 Bicyclerd Ltd Bt1718 for use in treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600911D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage;Brenda A. Kellogg;《Bioconjugate Chem.》;20110322;第22卷(第4期);全文 *

Also Published As

Publication number Publication date
DK3452096T3 (da) 2025-03-03
JP2019523214A (ja) 2019-08-22
US10994019B2 (en) 2021-05-04
CN109414510A (zh) 2019-03-01
GB201607827D0 (en) 2016-06-15
US20190134213A1 (en) 2019-05-09
JP6942147B2 (ja) 2021-09-29
EP3452096B1 (en) 2025-01-29
WO2017191460A1 (en) 2017-11-09
ES3010545T3 (en) 2025-04-03
EP3452096A1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
CN109414510B (zh) Mt1-mmp特异性双环肽-毒素缀合物
US11672868B2 (en) Bicyclic peptide ligands specific for MT1-MMP
CN110506049B (zh) 用于结合mt1-mmp的肽配体
CN113518648B (zh) Mt1-mmp特异性的双环肽配体
JP2025020121A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
CN114521197A (zh) 异串联双环肽复合物
CN113383007A (zh) Caix特异性的双环肽配体
CN113383074A (zh) Caix特异性的双环肽配体
CN113260420A (zh) Pd-l1特异性的双环肽配体
CN111712264A (zh) 特异于epha2的双环肽配体
CN112585157A (zh) 用于结合整联蛋白αvβ3的肽配体
CN113613728A (zh) 整联蛋白αvβ3特异性的双环肽配体
CN113507960A (zh) Psma特异性的双环肽配体
CN113439088A (zh) 整联蛋白αvβ3特异性的双环肽配体
CN113543813A (zh) Cd38特异性的双环肽配体
CN113507961A (zh) FAPα特异性的双环肽配体
HK40058108A (en) Bicyclic peptide ligands specific for mt1-mmp
RU2824959C2 (ru) Бициклические пептидные лиганды, специфичные для mt1-mmp
CN118234517A (zh) 双环肽配体药物偶联物
HK1243438B (en) Bicyclic peptide ligands specific for mt1-mmp

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant